<DOC>
	<DOCNO>NCT02407353</DOCNO>
	<brief_summary>This phase 1 investigator-and-subject blind , sponsor open , randomize , placebo control , parallel study healthy subject evaluate pharmacodynamics effect single oral dos PF-06648671 CSF Aβ concentration use serial CSF sample methodology .</brief_summary>
	<brief_title>A Study Evaluate Pharmacodynamic Effects Single Oral Doses PF-06648671 β-Amyloid ( Aβ ) Concentrations Cerebrospinal Fluid ( CSF )</brief_title>
	<detailed_description>This study investigator-and-subject blind , sponsor open , randomize , placebo-controlled , parallel study healthy subject evaluate central ( CSF ) peripheral ( plasma ) pharmacodynamics effect ( Abeta ) 36 hour post single dos PF-06648671 . Two cohort run sequential . first cohort evaluate Abeta effect top dose 300 mg PF-06648671 second cohort evaluate Abeta effect top dose ( subject require ) and/or 1-2 low dos</detailed_description>
	<criteria>Healthy male and/or female subject non childbearing potential BMI 17.5 30.5 kg/m2 total body weight &gt; 50 kg ( 110 lb ) Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated asymptomatic , seasonal allergy time dose ) Treatment investigational drug within 30 day ( determined local requirement ) 5 halflives precede first dose study medication ( whichever longer ) Subjects history significant active bleeding , coagulation disorder clinically significant find prothrombin time/ partial thromboplastin time/International Normalized Ratio ( PT/PTT/INR ) Screening Subjects low spinal malformation ( physical examination ) , local spinal infection , abnormality would exclude puncture ( LP ) Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Double blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Parallel Design</keyword>
	<keyword>CSF Aβ Concentrations</keyword>
	<keyword>PF-06648671</keyword>
</DOC>